This appointment comes at a crucial time for Tollys, with the successful preparation of the next fundraising campaign to finance the first phase I clinical trials, which are scheduled to launch in 2022.
FREMONT, CA: Tollys, a biopharmaceutical firm developing TL-532, the first synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, recently announced the appointment of Philippe Goupit as Chairman of the Board of Directors. This appointment comes at a crucial time for Tollys, with the successful preparation of the next fundraising campaign to finance the first phase I clinical trials, which are scheduled to launch in 2022.
“We are thrilled to appoint Philippe Goupit as chairman of the board. His valuable experience and skills will support our ambitions and help strengthen our board of directors at a key stage,” said Jacques-Fran§ois Martin, co-founder and former chairman of the board.
Tollys identified and patented a family of TLR3 agonists and picked TL-532 as its lead candidate. TL-532 is a structurally specified double-stranded, synthetically formed, and highly specific to the TLR3 receptor.
The TLR3 receptor’s specificity and its established 70 base pair sequence separate TL-532 from all other TLR3 agonists studied in clinical trials to date.
“I am honored and very excited to take up this position at Tollys at this specific stage in the development of the company. Thanks to the critical milestones already achieved by the co-founders in establishing the preclinical proof-of-concept of TL-532, it has the potential to become a breakthrough therapy in immuno-oncology,” said Philippe Goupit. “The team, led by Vincent Charlon, Tollys CEO, is excellent and fully capable of meeting the coming challenges within the company.”
In his 35-year career, Philippe worked with various pharmaceutical firms, most recently Sanofi, where he spent more than 20 years; in corporate affairs, deal-making, and strategic positions at the highest global level. Jacques-Francois Martin, co-founder and former chairman of the board of directors, will remain on the board of directors.